Moderator: Sherin Moideen, MD, DFAPA
Thomas Kaiser, MD; Jay Vora, MD
This case discussed a 68-year-old African American male with treatment-resistant tardive dyskinesia. The patient had previously been prescribed multiple antipsychotics (haloperidol and quetiapine) during a previous hospitalization. Unfortunately, he developed severe tardive dyskinesia as a result of antipsychotic treatment which has contributed to significant challenges in his daily life. The patient has previously trialed valbenazine, amantadine, and clonazepam for tardive dyskinesia symptoms with minimal relief. He is currently in the process of transitioning from valbenazine to deutetrabenazine in hopes of better controlling his tardive dyskinesia symptoms.
This case highlighted some of the challenges in treating patients with severe tardive dyskinesia and discussed some potential future treatment options. The case also emphasized the importance of mitigating unnecessary polypharmacy.
